MovDisordV3, PubMed, Checkpoint, bibRecord, 002E44

Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.

Identifieur interne : 002E44 ( PubMed/Checkpoint ); précédent : 002E43; suivant : 002E45

Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.

Auteurs : Giovanni Lagalla [Italie] ; Marzia Millevolte ; Marianna Capecci ; Leandro Provinciali ; Maria Gabriella Ceravolo

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.

RBID : pubmed:16440332

English descriptors

KwdEn :
- Aged, Botulinum Toxins, Type A (therapeutic use), Double-Blind Method, Female, Humans, Male, Middle Aged, Neuromuscular Agents (therapeutic use), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Sialorrhea (drug therapy), Sialorrhea (etiology).
MESH :
- chemical , therapeutic use : Botulinum Toxins, Type A, Neuromuscular Agents.
- complications : Parkinson Disease.
- drug therapy : Parkinson Disease, Sialorrhea.
- etiology : Sialorrhea.
- physiopathology : Parkinson Disease.
- Aged, Double-Blind Method, Female, Humans, Male, Middle Aged.

Abstract

To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double-blind, randomized, placebo-controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gland or placebo without using ultrasound guidance. Subjects treated with BoNTX experienced a reduction in both drooling frequency and familial and social disability (TimexGroup effect: P<0.01), as well as in saliva production (Time x Group effect: P<0.0001). No adverse events were recorded. BoNTX injections are safe and effective treatment for the management of PD-related drooling.

DOI: 10.1002/mds.20793
PubMed: 16440332

Affiliations:

Italie

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002D75
to stream PubMed, to step Curation: 002D75

Links to Exploration step

pubmed:16440332

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.</title>
<author><name sortKey="Lagalla, Giovanni" sort="Lagalla, Giovanni" uniqKey="Lagalla G" first="Giovanni" last="Lagalla">Giovanni Lagalla</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinica di Neuroriabilitazione, Dipartimento di Neuroscienze, Università Politecnica delle Marche, Az. Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Clinica di Neuroriabilitazione, Dipartimento di Neuroscienze, Università Politecnica delle Marche, Az. Ospedaliero Universitaria Ospedali Riuniti, Ancona</wicri:regionArea>
<wicri:noRegion>Ancona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Millevolte, Marzia" sort="Millevolte, Marzia" uniqKey="Millevolte M" first="Marzia" last="Millevolte">Marzia Millevolte</name>
</author>
<author><name sortKey="Capecci, Marianna" sort="Capecci, Marianna" uniqKey="Capecci M" first="Marianna" last="Capecci">Marianna Capecci</name>
</author>
<author><name sortKey="Provinciali, Leandro" sort="Provinciali, Leandro" uniqKey="Provinciali L" first="Leandro" last="Provinciali">Leandro Provinciali</name>
</author>
<author><name sortKey="Ceravolo, Maria Gabriella" sort="Ceravolo, Maria Gabriella" uniqKey="Ceravolo M" first="Maria Gabriella" last="Ceravolo">Maria Gabriella Ceravolo</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="doi">10.1002/mds.20793</idno>
<idno type="RBID">pubmed:16440332</idno>
<idno type="pmid">16440332</idno>
<idno type="wicri:Area/PubMed/Corpus">002D75</idno>
<idno type="wicri:Area/PubMed/Curation">002D75</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002E44</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.</title>
<author><name sortKey="Lagalla, Giovanni" sort="Lagalla, Giovanni" uniqKey="Lagalla G" first="Giovanni" last="Lagalla">Giovanni Lagalla</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinica di Neuroriabilitazione, Dipartimento di Neuroscienze, Università Politecnica delle Marche, Az. Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Clinica di Neuroriabilitazione, Dipartimento di Neuroscienze, Università Politecnica delle Marche, Az. Ospedaliero Universitaria Ospedali Riuniti, Ancona</wicri:regionArea>
<wicri:noRegion>Ancona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Millevolte, Marzia" sort="Millevolte, Marzia" uniqKey="Millevolte M" first="Marzia" last="Millevolte">Marzia Millevolte</name>
</author>
<author><name sortKey="Capecci, Marianna" sort="Capecci, Marianna" uniqKey="Capecci M" first="Marianna" last="Capecci">Marianna Capecci</name>
</author>
<author><name sortKey="Provinciali, Leandro" sort="Provinciali, Leandro" uniqKey="Provinciali L" first="Leandro" last="Provinciali">Leandro Provinciali</name>
</author>
<author><name sortKey="Ceravolo, Maria Gabriella" sort="Ceravolo, Maria Gabriella" uniqKey="Ceravolo M" first="Maria Gabriella" last="Ceravolo">Maria Gabriella Ceravolo</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neuromuscular Agents (therapeutic use)</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Sialorrhea (drug therapy)</term>
<term>Sialorrhea (etiology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
<term>Sialorrhea</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Sialorrhea</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double-blind, randomized, placebo-controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gland or placebo without using ultrasound guidance. Subjects treated with BoNTX experienced a reduction in both drooling frequency and familial and social disability (TimexGroup effect: P<0.01), as well as in saliva production (Time x Group effect: P<0.0001). No adverse events were recorded. BoNTX injections are safe and effective treatment for the management of PD-related drooling.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16440332</PMID>
<DateCreated><Year>2006</Year>
<Month>05</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted><Year>2006</Year>
<Month>10</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2010</Year>
<Month>11</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>21</Volume>
<Issue>5</Issue>
<PubDate><Year>2006</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.</ArticleTitle>
<Pagination><MedlinePgn>704-7</MedlinePgn>
</Pagination>
<Abstract><AbstractText>To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double-blind, randomized, placebo-controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gland or placebo without using ultrasound guidance. Subjects treated with BoNTX experienced a reduction in both drooling frequency and familial and social disability (TimexGroup effect: P<0.01), as well as in saliva production (Time x Group effect: P<0.0001). No adverse events were recorded. BoNTX injections are safe and effective treatment for the management of PD-related drooling.</AbstractText>
<CopyrightInformation>Copyright (c) 2006 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lagalla</LastName>
<ForeName>Giovanni</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Clinica di Neuroriabilitazione, Dipartimento di Neuroscienze, Università Politecnica delle Marche, Az. Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Millevolte</LastName>
<ForeName>Marzia</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Capecci</LastName>
<ForeName>Marianna</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Provinciali</LastName>
<ForeName>Leandro</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ceravolo</LastName>
<ForeName>Maria Gabriella</ForeName>
<Initials>MG</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009465">Neuromuscular Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber>
<NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D019274">Botulinum Toxins, Type A</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009465">Neuromuscular Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D012798">Sialorrhea</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>1</Month>
<Day>28</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>10</Month>
<Day>19</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>1</Month>
<Day>28</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.20793</ArticleId>
<ArticleId IdType="pubmed">16440332</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Italie</li>
</country>
</list>
<tree><noCountry><name sortKey="Capecci, Marianna" sort="Capecci, Marianna" uniqKey="Capecci M" first="Marianna" last="Capecci">Marianna Capecci</name>
<name sortKey="Ceravolo, Maria Gabriella" sort="Ceravolo, Maria Gabriella" uniqKey="Ceravolo M" first="Maria Gabriella" last="Ceravolo">Maria Gabriella Ceravolo</name>
<name sortKey="Millevolte, Marzia" sort="Millevolte, Marzia" uniqKey="Millevolte M" first="Marzia" last="Millevolte">Marzia Millevolte</name>
<name sortKey="Provinciali, Leandro" sort="Provinciali, Leandro" uniqKey="Provinciali L" first="Leandro" last="Provinciali">Leandro Provinciali</name>
</noCountry>
<country name="Italie"><noRegion><name sortKey="Lagalla, Giovanni" sort="Lagalla, Giovanni" uniqKey="Lagalla G" first="Giovanni" last="Lagalla">Giovanni Lagalla</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E44 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002E44 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:16440332
   |texte=   Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:16440332" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.

Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki